ArticleCureus2025
Low-Dose Sublingual Ketamine for the Treatment of Raynaud's Phenomenon.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Raynaud's phenomenon is a vascular disorder characterized by episodic vasospasm of small arteries, primarily affecting the hands and feet. Standard treatment strategies typically include lifestyle modifications to avoid cold exposure and stress, alongside pharmacological interventions aimed at increasing blood flow and reducing vascular constriction. Ketamine, an FDA-approved anesthetic since 1970, exhibits analgesic and vasodilatory properties that may enhance perfusion. This case report describes a woman with primary Raynaud's phenomenon whose symptoms improved significantly during treatment with low-dose sublingual ketamine prescribed for treatment-resistant depression. Further research into the use of this safe and inexpensive medicine as a treatment for Raynaud's phenomenon is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.